icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Rates and predictors of HBsAg loss after discontinuation of effective long-term entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: Results from the prospective DARING-B Greek study.
 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
 
M Papatheodoridi1, E Rigopoulou2, E Hadziyannis3, K Zachou2, V Xourafas1, A Lyberopoulou2, N Gatselis2, J, S Manolakopoulos1,3, GN Dalekos2, GV Papatheodoridis1.

0430181

0430182

0430183

0430184

0430185

0430186

0430187

0430188

0430189

04301810

04301811

04301812

04301813

04301814